Physician profile
Olusegun Ogunfowora
NPI 1275602963
$3,249.69
in general payments reported to CMS, 2019-2025
31 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $320 · 2022: $331 · 2023: $755 · 2024: $705 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $406.96 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $312.23 | 2020-2024 | Farxiga, Lokelma, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.87 | 2024-2025 | Caplyta |
| Janssen Biotech, INC. | $252.07 | 2021-2023 | Symtuza |
| Bayer Healthcare Pharmaceuticals INC. | $248.95 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $230.90 | 2022-2024 | Xarelto |
| Lundbeck LLC | $148.83 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $148.61 | 2022-2025 | Nuplazid |
| Boston Scientific Corporation | $124.15 | 2024-2025 | Watchman Flx |
| Novo Nordisk INC | $122.90 | 2023-2025 | Rybelsus |
| Viiv Healthcare Company | $107.99 | 2023-2025 | Dovato, Cabenuva |
| Novartis Pharmaceuticals Corporation | $105.59 | 2021-2023 | |
| Janssen Products, Lp | $99.95 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $63.16 | 2024-2025 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.47 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $56.92 | 2023-2024 | |
| Ucb, INC. | $55.20 | 2021-2022 | |
| Ardelyx, INC. | $51.15 | 2024 | Ibsrela |
| Renalytix Ai, INC. | $43.72 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $42.01 | 2021-2025 | Kisunla |
| Gilead Sciences, INC. | $39.46 | 2022-2023 | |
| Glaxosmithkline, LLC. | $39.05 | 2025 | Trelegy Ellipta |
| Avanir Pharmaceuticals, INC. | $34.79 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $31.35 | 2023 | Ingrezza |
| Pfizer INC. | $29.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.63 | 2023 | Austedo Xr |
| Shield Therapeutics INC | $23.76 | 2025 | |
| Allergan, INC. | $20.68 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.59 | 2025 | Amvuttra |
| Genzyme Corporation | $16.59 | 2022 | |
| Merck Sharp & Dohme LLC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusegun Ogunfowora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.